Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

livmoniplimab

A humanized monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator, glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, livmoniplimab selectively targets and binds to GARP which interferes with the production and release of active TGFbeta by regulatory T cells (Tregs). Selective inhibition of the release of TGFbeta from Tregs leads to a reversal of immunosuppression thereby increasing the immune response to tumor cells. GARP, a leucine-rich repeat-containing protein, is essential for the expression of TGFbeta on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-GARP monoclonal antibody ABBV-151
anti-glycoprotein A repetitions predominant monoclonal antibody ABBV-151
Code name:ABBV 151
ABBV-151
ABBV151
ARGX 115
ARGX-115
ARGX115
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search